Infantile Hemangiomas Cleared by Combined Therapy With Pulsed Dye Laser and Propranolol.

Abstract

Oral propranolol is the first-line therapy for infantile hemangioma. Combining it with pulse dye laser (PDL) (595nm-long PDL) could reduce treatment duration and sequelae incidence and severity. To determine the effect of PDL-propranolol treatment on duration to cure and sequelae. All consecutive patients with infantile hemangioma who were cured by PDL-propranolol treatment were identified. In the 27 cases, average age at treatment start was 4.3 ± 3.8 months, mean tumor diameter was 11.1 ± 14.0 cm2, and tumor-type was most common (72.4% of lesions). The patients received 9.8 ± 10.5 PDL sessions. After ensuring patients had no physical contraindications, including heart disease, oral propranolol was started at 1 mg/kg/d, increased up to 3 mg/kg/d as a maintenance dose. Mean propranolol treatment duration was 11.1 ± 4.9 months. Total treatment duration was 15.3 ± 10.8 months. Our data in the context of recent literature suggest combining propranolol with PDL may reduce propranolol duration without increasing harms.